NuVasive Rating Lowered to Neutral at Zacks (NUVA)
NuVasive (NASDAQ:NUVA) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a report issued on Thursday, Stock Ratings Network.com reports. They currently have a $35.40 target price on the stock. Zacks‘ price target suggests a potential upside of 9.50% from the stock’s previous close.
Shares of NuVasive (NASDAQ:NUVA) traded down 2.75% during mid-day trading on Thursday, hitting $31.44. The stock had a trading volume of 319,897 shares. NuVasive has a one year low of $15.70 and a one year high of $33.91. The stock’s 50-day moving average is $32.58 and its 200-day moving average is $27.04. The company’s market cap is $1.403 billion.
NuVasive (NASDAQ:NUVA) last announced its earnings results on Tuesday, October 29th. The company reported $0.39 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.24 by $0.15. The company had revenue of $169.20 million for the quarter, compared to the consensus estimate of $158.30 million. During the same quarter in the previous year, the company posted $0.23 earnings per share. The company’s revenue for the quarter was up 14.0% on a year-over-year basis.
In other NuVasive news, SVP Craig Hunsaker sold 4,275 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $32.10, for a total transaction of $137,227.50. Following the sale, the senior vice president now directly owns 24,980 shares of the company’s stock, valued at approximately $801,858. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of other analysts have also recently weighed in on NUVA. Analysts at Barclays raised their price target on shares of NuVasive from $30.00 to $32.00 in a research note to investors on Monday, December 2nd. They now have an “equal weight” rating on the stock. Separately, analysts at RBC Capital raised their price target on shares of NuVasive from $31.00 to $35.00 in a research note to investors on Friday, November 15th. They now have a “sector perform” rating on the stock. Finally, analysts at Needham & Company raised their price target on shares of NuVasive from $35.00 to $40.00 in a research note to investors on Friday, November 15th. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating, nine have given a hold rating and eight have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $29.15.
NuVasive, Inc (NASDAQ:NUVA) is a medical device company.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.